News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Most viewed in the last 7 days from JAMA Oncology
Photo taken from JAMA Oncology/LinkedIn
Apr 3, 2024, 06:05

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”

Additional information.
Source: JAMA Oncology/LinkedIn

cancer cell death chemo-immunotherapy JAMA Oncology NSCLC OncoDaily Oncology patients
Special Coverage
Blog
Apr 1, 2025, 19:09
Sally Susman: Thank you for joining me for Memoir March
Blog
Apr 1, 2025, 19:03
Megan-Claire J. Chase: Amazing team from Pink Warrior Angels at the exhibitor table right next to mine
Blog
Apr 1, 2025, 19:03
AIQ Solutions Tackles the Complex Reality of Unequal Metastatic Cancer Treatment Responses - CancerX
Blog
Apr 1, 2025, 18:58
Kevin Jackson Announces New Role as Lead Events Manager at UF Health Cancer Center
Blog
Apr 1, 2025, 18:48
Understanding Abnormal Coagulation at EPHOC 2025 - MENA Conference
Blog
Apr 1, 2025, 18:43
Debra Montague Joins Medscape Faculty Steering Committee as Patient Representative
Blog
Apr 1, 2025, 18:37
Binay Shah: Three Timely Levers to help bridge growing gap in Cancer Care
Insight
Apr 1, 2025, 18:33
Fumiko Ladd Chino: Over 1,200 scientists may leave the US due to disruptions from the Trump administration
Blog
Apr 1, 2025, 18:29
How EveryGrant is Helping Grantmakers Make a Global Impact - Conquer Cancer, the ASCO Foundation
Blog
Apr 1, 2025, 18:28
How tobacco smoking contributes to development of cancers of the head and neck - IARC/WHO
Blog
Apr 1, 2025, 18:26
Benjamin Perrotta: St. Baldricks was a success
Blog
Apr 1, 2025, 18:22
Last days to submit your abstract and topic proposal for SIOP 2025